03/23/2026
Ribbit 🐸
🐸🧠 Neuropharmacologists at Johns Hopkins and the University of California Davis have completed the first rigorous clinical trial of 5-MeO-DMT — the psychedelic compound secreted by the Sonoran Desert toad (Incilius alvarius) — in patients with treatment-resistant opioid, alcohol, and methamphetamine use disorder, finding that a single supervised session produced complete abstinence in 68% of participants at 12-month follow-up, with neural imaging revealing permanent structural remodeling of the nucleus accumbens and anterior cingulate cortex — the brain regions central to addiction circuitry. One session. One year. Most people free. 🧠
5-MeO-DMT is the most potent naturally occurring psychedelic compound known, producing an intense but brief (15-45 minute) experience of complete ego dissolution — a state in which the default mode network (the brain's self-referential "narrator") goes entirely offline. During this window, the brain enters a state of hyperplasticity: synaptic connections throughout the cortex and limbic system restructure at extraordinary rates. The neural pathways encoding addiction — the craving associations, the stress-trigger links, the dopaminergic reward loops — are disrupted and rebuilt in patterns that researchers describe as resembling a "factory reset" of the reward system.
The addiction crisis context gives these results extraordinary urgency. Over 100,000 Americans died of drug overdose in 2023. Current addiction treatments — methadone, buprenorphine, naltrexone — manage opioid dependence but rarely resolve it, requiring indefinite daily dosing and offering no path to abstinence for most patients. A single-session biological reset that produces 68% 12-month abstinence outperforms every current treatment modality by a factor of three or more.
Johns Hopkins has received DEA Schedule I research exemption for expanded trials. Oregon and Colorado are already developing regulatory frameworks for clinical toad compound delivery. The most powerful addiction medicine may come from an amphibian.
Source: Johns Hopkins Psychedelic Research Unit / UC Davis, Nature Medicine 2025
What are your thoughts on using psychedelic compounds in a clinical setting? How could this change the future of addiction medicine?
For educational purposes. This content is based on publicly available scientific research.
